1stOncology™: Cancer Intelligence Service – Page 12695 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Asia Matters presents "Special Award to Investors in Ireland" to WuXi Biologics

On December 23, 2019 WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open access technology platform for biologics, the all-in-one solution for research, development and manufacturing offers biological preparations, reported the "Special Award to Investors in Ireland " at the Asia Matters Global Business Summit 2019 (Press release, WuXi Biologics, DEC 23, 2019, View Source [SID1234552594]). This is Ireland’s only Asian think tank that specifically deals with trade, investment and economic issues, as well as international relations between the EU and Asia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The "Special Award to Investors in Ireland " is given to a newly established company that invests in Ireland. The emphasis is on a long-term and significant contribution to economic growth, employment, research and corporate social responsibility (CSR). Last year, WuXi Biologics a "Factory of the Future" for the production of biologicals was built in Dundalk. A second investment was announced last month by its subsidiary WuXi Vaccines. A new vaccine production facility is to be built at the Dundalk site.

"We are extremely pleased to receive this award from Asia Matters . It demonstrates the great progress we are making in Ireland, "said Dr. Chris Chen , CEO of WuXi Biologics, speaking at the summit." Based on our leading expertise and expertise in the high-growth biology business, we will continue to be our local and global partners provide a robust and world-class supply chain for the benefit of patients around the world. "

Universal Health Services, Inc. To Present At The 38th Annual J.P. Morgan Healthcare Conference

On December 23, 2019 Universal Health Services, Inc. (NYSE: UHS) reported that Steve Filton, Executive Vice President and Chief Financial Officer will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Monday, January 13, 2020 at 2:00 p.m. (Pacific Time) (Press release, Universal Health Services, DEC 23, 2019, View Source [SID1234552593]). A live audio webcast of the presentation will be available on the Company’s website (www.uhsinc.com). For those unable to listen to the live webcast, a replay will be available on the Company’s website for 90 days following the conferences.

Universal Health Services (NYSE: UHS) is one of the largest and most respected hospital management companies in the nation. For nearly 40 years, UHS and its affiliates have focused on meeting patients’ healthcare needs across hundreds of local communities. Today, UHS subsidiaries own and/or operate 394 inpatient and outpatient facilities including acute care hospitals, behavioral health facilities, ambulatory centers, freestanding emergency departments, and urgent care centers in 37 states, Washington, D.C., the United Kingdom, Puerto Rico, and the U.S. Virgin Islands. For additional information on the Company, visit our web site: View Source

Illumina to Webcast Upcoming Investor Conference Presentation

On December 23, 2019 Illumina, Inc. (NASDAQ:ILMN) reported that its executives will be speaking at the following investor conference and invite investors to participate via webcast (Press release, Illumina, DEC 23, 2019, View Source [SID1234552592]).

J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2020
Presentation at 8:30am Pacific Time followed by a Q&A Session at 9am Pacific Time

The live webcasts can be accessed in the Investor Relations section of Illumina’s website under the "company" tab at www.illumina.com. Replays will be posted on Illumina’s website after the event and will be available for at least 30 days following.

Exicure Announces the Closing of its Offering of Common Stock

On December 23, 2019 Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, reported the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $2.75 per share (Press release, Exicure, DEC 23, 2019, View Source [SID1234552591]).

Exicure received gross proceeds of $27.50 million from the sale of common stock in the offering, prior to deducting the underwriting discounts and commissions and estimated offering expenses payable by it. Exicure intends to use the net proceeds from the offering to advance AST-008 through a Phase 1b/2 clinical trial; to initiate a second arm in its Phase 1b/2 clinical trial in cutaneous squamous cell carcinoma; to develop an SNA-based therapeutic candidate for the treatment of Friedreich’s ataxia, initiate IND-enabling studies and advance it into Phase 1 clinical trials; to develop a second SNA therapeutic candidate for a neurology condition and initiate IND-enabling studies; and for general corporate purposes.

Guggenheim Securities acted as sole book-running manager for the offering. Chardan acted as lead manager for the offering. H.C. Wainwright & Co. and Ladenburg Thalmann acted as co-managers for the offering.

The securities described above were offered by Exicure pursuant to a shelf registration statement on Form S-3 (No. 333-230175) that was declared effective by the Securities and Exchange Commission (SEC) on July 24, 2019. A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC on August 1, 2019 and is available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained from: Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-5548, or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

CEL-SCI Announces Proposed Underwritten Public Offering of Common Stock

On December 23, 2019 CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, reported that it intends to offer shares of its common stock for sale in an underwritten public offering (Press release, Cel-Sci, DEC 23, 2019, View Source [SID1234552590]). In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments. The Company intends to use the net proceeds from this offering to fund the continued development of Multikine*, LEAPS and for other general corporate purposes. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Aegis Capital Corp. is acting as sole bookrunner for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-226558) previously filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective by the SEC on August 24, 2018. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at View Source Electronic copies of the preliminary prospectus supplement and the accompanying prospectus when available, may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at [email protected], or by telephone at (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.